海利生物
(603718)
| 流通市值：45.82亿 | | | 总市值：46.29亿 |
| 流通股本：6.49亿 | | | 总股本：6.56亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 149,742,032.7 | 109,776,927.64 | 61,792,980.19 | 271,039,818.26 |
| 营业收入 | 149,742,032.7 | 109,776,927.64 | 61,792,980.19 | 271,039,818.26 |
| 二、营业总成本 | 109,631,357.1 | 76,009,089.52 | 41,355,751.57 | 241,171,112.08 |
| 营业成本 | 38,774,583.43 | 25,125,479.07 | 14,854,132.26 | 107,861,963.96 |
| 税金及附加 | 1,497,413.05 | 987,951.12 | 450,713.31 | 3,915,313.05 |
| 销售费用 | 26,624,714.54 | 20,406,702.4 | 10,373,489.06 | 49,329,513.58 |
| 管理费用 | 29,539,063.4 | 20,112,692.25 | 11,291,949.78 | 62,623,479.47 |
| 研发费用 | 17,121,103.76 | 12,163,351.77 | 6,040,598.06 | 24,454,326.46 |
| 财务费用 | -3,925,521.08 | -2,787,087.09 | -1,655,130.9 | -7,013,484.44 |
| 其中:利息费用 | 918,548.87 | 772,082.74 | - | 5,490,985.78 |
| 其中:利息收入 | 5,727,959.84 | 4,271,680.41 | 2,145,710.13 | 2,206,066.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,721,554.35 | 1,501,099.14 | 429,155.48 | -12,761,890.33 |
| 加:投资收益 | 355,230.63 | 223,930.93 | 284,477.72 | 158,406,545.28 |
| 资产处置收益 | 223,211.51 | 223,211.51 | - | - |
| 资产减值损失(新) | - | - | - | -3,714,782.36 |
| 信用减值损失(新) | -1,150,505.29 | -694,816.64 | -1,562,628.63 | -3,938,168.64 |
| 其他收益 | 1,787,600.67 | 1,633,461.06 | 1,340,545.04 | 6,665,886.94 |
| 四、营业利润 | 44,047,767.47 | 36,654,724.12 | 20,928,778.23 | 174,526,297.07 |
| 加:营业外收入 | 64,755.54 | 64,225.65 | 64,224.89 | 34,337,569.37 |
| 减:营业外支出 | 176,896.04 | 122,375.17 | 1,997.54 | 746,410.66 |
| 五、利润总额 | 43,935,626.97 | 36,596,574.6 | 20,991,005.58 | 208,117,455.78 |
| 减:所得税费用 | 6,313,290.19 | 4,617,231.84 | 3,053,679.42 | 26,481,859.77 |
| 六、净利润 | 37,622,336.78 | 31,979,342.76 | 17,937,326.16 | 181,635,596.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,622,336.78 | 31,979,342.76 | 17,937,326.16 | 181,635,596.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 20,329,681.8 | 18,234,848.34 | 10,901,715.1 | 171,180,295.61 |
| 少数股东损益 | 17,292,654.98 | 13,744,494.42 | 7,035,611.06 | 10,455,300.4 |
| 扣除非经常损益后的净利润 | 16,473,024.06 | 15,469,536.74 | 9,199,267.3 | 10,581,377.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.03 | 0.02 | 0.27 |
| (二)稀释每股收益 | 0.03 | 0.03 | 0.02 | 0.26 |
| 八、其他综合收益 | - | - | - | 2,571,231.12 |
| 归属于母公司股东的其他综合收益 | - | - | - | 2,571,231.12 |
| 九、综合收益总额 | 37,622,336.78 | 31,979,342.76 | 17,937,326.16 | 184,206,827.13 |
| 归属于母公司股东的综合收益总额 | 20,329,681.8 | 18,234,848.34 | 10,901,715.1 | 173,751,526.73 |
| 归属于少数股东的综合收益总额 | 17,292,654.98 | 13,744,494.42 | 7,035,611.06 | 10,455,300.4 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |